Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs The Coca-Cola Co K — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while The Coca-Cola Co K trades at $82.71 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 44.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and The Coca-Cola Co K pays a 2.55% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KO | |
|---|---|---|
Market Cap | $8.04B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $84.25 |
52-Week Low | $241.71 | $65.67 |
Enterprise Value | $7.85B | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Coca-Cola (KO) trades at $83.25, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying activity. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.86 exceeding expectations. Fundamentals show solid profitability with a 27.8% net income margin and 45.8% ROE, while valuation ratios like P/E of 26.13 reflect premium pricing. Recent news highlights steady demand trends and dividend reliability, with the stock offering a 2.5% yield.
The outlook for KO remains positive given consistent earnings outperformance, analyst consensus buy rating (60% buy), and a $89.75 price target implying 7.8% upside. Key risks include regional demand volatility in Asia and high debt levels, but the company's strong brand and cash flow support dividend sustainability. Investors may find value in its defensive qualities and growth potential from global events like the FIFA World Cup 2026 sponsorship.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
